Demethoxycurcumin

Demethoxycurcumin

SCHEMBL9907007

COc1cc(/C=C/C(O)=C/C(=O)/C=C/c2ccc(O)cc2)ccc1O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.83
BACE1 P56817 5/20 0.83
CYP2D6 P10635 3/20 0.72
NFKB1 P19838 3/20 0.72
NFKB2 Q00653 3/20 0.72
RELA Q04206 3/20 0.72
CYP1A2 P05177 2/20 0.72
ALOX5 P09917 2/20 0.72
HSD11B1 P28845 2/20 0.72
STAT3 P40763 2/20 0.72
NFE2L2 Q16236 2/20 0.72
ABCB1 P08183 2/20 0.70
AKR1B1 P15121 2/20 0.70
MAOA P21397 2/20 0.70
MAOB P27338 2/20 0.70
GLO1 Q04760 2/20 0.69
HDAC1 Q13547 3/20 0.69
HDAC2 Q92769 3/20 0.69
HDAC8 Q9BY41 3/20 0.69
SNCA P37840 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4545726 1.00 GSK3B (0.83) GSK3BBACE1CYP2D6NFKB1NFKB2
Demethoxycurcumin SCHEMBL29374534 1.00 GSK3B (0.83) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL3680675 0.95 GSK3B (0.87) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL29370884 0.95 GSK3B (0.87) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL3433171 0.95 GSK3B (0.87) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL242412 0.95 GSK3B (0.87) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL29855588 0.95 GSK3B (0.87) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL6727006 0.95 GSK3B (0.87) GSK3BBACE1CYP2D6NFKB1NFKB2
Methylcurcumin SCHEMBL9907002 0.91 GSK3B (0.81) GSK3BBACE1CYP2D6NFKB1NFKB2
SCHEMBL22902413 0.91 GSK3B (0.81) GSK3BBACE1CYP2D6NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150232642-A1 POLYMERIC NANOPARTICLES COMPRISING TURMERIC XEROX CORPORATION (US) 2015-08-20 US disclosed
US-8198323-B2 Curcumin analogues and uses thereof THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-06-12 US disclosed
US-8198323-B2 Curcumin analogues and uses thereof THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-06-12 US disclosed
US-20100197784-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF The University of North Carlina at Chapel Hill (US) 2010-08-05 US disclosed
US-20100197784-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF The University of North Carlina at Chapel Hill (US) 2010-08-05 US disclosed
US-7728043-B2 Methods for treatment of beta-amyloid protein-induced ocular disease KIM DARRICK S H L 2010-06-01 US disclosed
US-7709535-B2 Curcumin analogues and uses thereof THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2010-05-04 US disclosed
US-7709535-B2 Curcumin analogues and uses thereof THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2010-05-04 US disclosed
US-7682636-B2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 METAPROTEOMICS, LLC (US) 2010-03-23 US disclosed
US-20090263522-A1 Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2 META PROTEOMICS, LLC 2009-10-22 US disclosed
US-20080161391-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF THE UNIVERSITY OF NORTH CAROLINA (US) 2008-07-03 US disclosed
US-20080161391-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF THE UNIVERSITY OF NORTH CAROLINA (US) 2008-07-03 US disclosed
US-20080146660-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2008-06-19 US disclosed
US-20080146660-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2008-06-19 US disclosed
US-7355081-B2 androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2008-04-08 US disclosed
US-7355081-B2 androgen receptor antagonists; certain cancers, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2008-04-08 US disclosed
US-20070141183-A1 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 METAPROTEOMICS, LLC (CA) 2007-06-21 US disclosed
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease KIM DARRICK S H 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146660-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF AR, NR5A1, BRDT GSK3B 2794/4885BACE1 3684/4885CYP2D6 1611/4885
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease APP, BACE1, GSAP GSK3B 222/4885BACE1 2/4885CYP2D6 3439/4885
US-20080161391-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF AR, NR5A1, BRDT GSK3B 2794/4885BACE1 3684/4885CYP2D6 1611/4885
US-20100197784-A1 NOVEL CURCUMIN ANALOGUES AND USES THEREOF AR, NR5A1, BRDT GSK3B 2794/4885BACE1 3684/4885CYP2D6 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.